Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cervix Lesion Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection

NCT03366493
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3
Interventions
FRD, Cytology, HPV testing, Colposcopy, ECC, Biospy
Combination Product · Other · Procedure
Lead sponsor
GY Highland Biotech LLC
Industry
Eligibility
20 Years to 60 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 3, 2026, 3:24 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03721978
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Matched Placebo, CELLECTRA™-5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions

NCT02172664
View directory record Official record
Conditions
Cervical Lesions
Interventions
Self etch enamel etching, selective etch protocol, Adhese Universal
Procedure · Device
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 3, 2026, 3:24 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

NCT03911076
View directory record Official record
Conditions
ASC-US, ASC-H, LSIL
Interventions
PVX-2, Placebo
Biological · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Sep 3, 2026, 3:24 AM EDT
Enrolling by invitation No phase listed Observational

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

NCT04266093
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix, Hematologic Malignacies
Interventions
GeneTherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Terminated No phase listed Observational

A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients

NCT00519272
View directory record Official record
Conditions
Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional

Noncarious Cervical Lesion Treatment Outcomes

NCT00867997
View directory record Official record
Conditions
Noncarious Cervical Lesions
Interventions
Chemoactive (remineralizing, neuroactive) dentifrice treatment, Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F, Clearfil S3 Bond; Premise Flowable resin-based composite
Other
Lead sponsor
Pearl Network
Network
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
17
States / cities
Darien, Connecticut • Potomac, Maryland • Southborough, Massachusetts + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

NCT00596258
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
A-007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Costa Mesa, California • Boynton Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2009 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional

The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia

NCT00653146
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Mindfulness-Based Stress Reduction, Healthy Lifestyles
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 3, 2026, 3:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia

NCT04274465
View directory record Official record
Conditions
Cervix Lesion, Cervical Cancer
Interventions
digital PCR (dPCR) assay
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 3, 2026, 3:24 AM EDT
Not listed Phase 2 Interventional

Diagnostic Imaging Aid for Management of Cervical Lesions

NCT02406365
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasias, Digital Colposcopy, Precancerous Cervical Lesions
Interventions
Diagnostic imaging aid for one-visit management of cervical lesions
Device
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scotchbond Universal Plus Compared to Scotchbond Universal With Filtek Universal Restorative to Restore Class V NCCLs

NCT05361746
View directory record Official record
Conditions
Class V Non-carious Cervical Dental Lesions
Interventions
Scotchbond Universal Plus Adhesive, Scotchbond Universal Adhesive
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

NCT00001073
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Honduras Liger Thermocoagulator Study

NCT03510273
View directory record Official record
Conditions
Cervix Cancer, Cervix Lesion
Interventions
Liger Medical Thermocoagulator
Device
Lead sponsor
PATH
Other
Eligibility
30 Years to 49 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive

NCT01464996
View directory record Official record
Conditions
Composite Restorations, Tooth Lesions
Interventions
Adhesive: OptiBond XTR; Composite: Herculite Ultra, Adhesive: OptiBond FL; Composite: Herculite Ultra
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 3, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

NCT02864147
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions
9-valent HPV vaccine, Imiquimod
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 3, 2026, 3:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings

NCT06810427
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
CervImage device
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 3, 2026, 3:24 AM EDT